文献速递血栓与止血造血干细胞移植与细胞治疗

接受治疗剂量依诺肝素的高级别胶质瘤患者颅内出血风险升高的预测

Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin.
PubMed 文献 · Blood · 2017-05-03

该匹配回顾性队列研究纳入133例高级别胶质瘤患者,经盲法影像学复核发现,接受依诺肝素者发生主要颅内出血的风险是未抗凝者的3倍以上(14.7% vs 2.5%;HR 3.37;95%CI 1.02-11.14)。依诺肝素组发生主要颅内出血者总生存显著更短(3.3 vs 10.2个月)。PANWARDS评分≥25分可识别全部主要颅内出血,敏感度100%、特异度40%。作者认为应考虑治疗性抗凝时需谨慎。

要点

  • 高级别胶质瘤患者接受依诺肝素后主要颅内出血发生率为14.7%,未抗凝者为2.5%(HR 3.37)。
  • 依诺肝素组发生主要颅内出血者总生存3.3个月,未抗凝者为10.2个月(log-rank P=.012)。
  • PANWARDS评分≥25分时敏感度100%、特异度40%,所有主要颅内出血均在此评分下发生。

核心结论

  • 高级别胶质瘤患者使用治疗剂量依诺肝素时需谨慎,因颅内出血风险增加且出血后预后差。
  • PANWARDS评分可能帮助临床医生识别抗凝后发生主要颅内出血风险最高的患者。

研究设计与样本

  • 匹配回顾性队列研究,对133例高级别胶质瘤患者进行盲法影像学复核。

主要发现

  • 诊断胶质瘤后,接受依诺肝素组发生主要颅内出血的可能性是未抗凝组的3倍(14.7% vs 2.5%;P=.036;HR 3.37;95%CI 1.02-11.14)。
  • 将依诺肝素作为时变协变量分析时,抗凝与出血风险增加超过13倍相关(HR 13.26;95%CI 3.33-52.85;P<.0001)。
  • 依诺肝素组发生主要颅内出血者总生存显著短于未抗凝组(3.3 vs 10.2个月;log-rank P=.012)。
  • 所有依诺肝素相关主要颅内出血均发生在PANWARDS评分≥25分时,敏感度100%(95%CI 63%-100%),特异度40%(95%CI 25%-56%)。

关键数值与推荐

  • PANWARDS评分≥25分对应主要颅内出血敏感度100%(95%CI 63%-100%)和特异度40%(95%CI 25%-56%)。

临床怎么用

  • 作者认为,鉴于颅内出血风险增加及主要出血后预后差,考虑对高级别胶质瘤患者进行治疗性抗凝时需谨慎。
  • PANWARDS评分可能协助临床医生识别抗凝后发生主要颅内出血风险最高的患者。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Venous thromboembolism occurs in up to one-third of patients with primary brain tumors. Spontaneous intracranial hemorrhage (ICH) is also a frequent occurrence in these patients, but there is limited data on the safety of therapeutic anticoagulation. To determine the rate of ICH in patients treated with enoxaparin, we performed a matched, retrospective cohort study with blinded radiology review for 133 patients with high-grade glioma. After diagnosis of glioma, the cohort that received enoxaparin was 3 times more likely to develop a major ICH than those not treated with anticoagulation (14.7% vs 2.5%; P = .036; hazard ratio [HR], 3.37; 95% confidence interval [CI], 1.02-11.14). When enoxaparin was analyzed as a time-varying covariate, anticoagulation was associated with a >13-fold increased risk of hemorrhage (HR, 13.26; 95% CI, 3.33-52.85; P < .0001). Overall survival was significantly shorter for patients who suffered a major ICH on enoxaparin compared with patients not receiving anticoagulation (3.3 vs 10.2 months; log-rank P = .012). We applied a validated ICH prediction risk score PANWARDS (platelets, albumin, no congestive heart failure, warfarin, age, race, diastolic blood pressure, stroke), and observed that all major ICHs on enoxaparin occurred in the setting of a PANWARDS score ≥25, corresponding with a sensitivity of 100% (95% CI, 63% to 100%) and a specificity of 40% (95% CI, 25% to 56%). We conclude that caution is warranted when considering therapeutic anticoagulation in patients with high-grade gliomas given the increased risk of ICH and poor prognosis after a major hemorrhage on anticoagulation. The PANWARDS score may assist clinicians in identifying the patients at greatest risk of suffering a major intracranial hemorrhage with anticoagulation.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Mantia C, Uhlmann EJ, Puligandla M, et al. Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin. Blood. 2017. PMID: 28468796. doi:10.1182/blood-2017-02-767285

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。